COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlLi (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.06-0.72]2/519/4579% improvementMareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Improvement, RR [CI]TreatmentControlTolouian (RCT)76%0.24 [0.01-8.03]death4852Tau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.43-0.87]14/7220/7339% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies44%0.56 [0.40-0.78]16/14831/14344% improvement5 bromhexine COVID-19 studiesc19bromhexine.com 6/14/21Tau​2 = 0.00; I​2 = 0.0%; Z = 3.41 (p = 0.00033)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]0/395/39Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]4852Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementAll studies91%0.09 [0.01-1.57]0/875/9191% improvement2 bromhexine COVID-19 mortality resultsc19bromhexine.com 6/14/21Tau​2 = 0.00; I​2 = 0.0%; Z = 1.65 (p = 0.05)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)82%0.18 [0.04-0.77]2/3911/39Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.77]2/3911/3982% improvementAll studies82%0.18 [0.04-0.77]2/3911/3982% improvement1 bromhexine COVID-19 ICU resultc19bromhexine.com 6/14/21Tau​2 = 0.00; I​2 = 0.0%; Z = 2.32 (p = 0.01)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Mikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies80%0.20 [0.01-3.97]0/252/2580% improvement1 bromhexine COVID-19 hospitalization resultc19bromhexine.com 6/14/21Tau​2 = 0.00; I​2 = 0.0%; Z = 1.06 (p = 0.15)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Tolouian (RCT)-75%1.75 [1.13-2.71]29/4818/52Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-75%1.75 [1.13-2.71]29/4818/52-75% improvementAll studies-75%1.75 [1.13-2.71]29/4818/52-75% improvement1 bromhexine COVID-19 case resultc19bromhexine.com 6/14/21Tau​2 = 0.00; I​2 = 0.0%; Z = 2.49 (p = 0.0064)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.01-1.59]0/395/3991% improvementTolouian (RCT)76%0.24 [0.01-8.03]death4852Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment76%0.24 [0.01-8.03]0/480/5276% improvementMikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP80%0.20 [0.01-3.97]0/252/2580% improvementAll studies87%0.13 [0.02-1.04]0/1127/11687% improvement3 bromhexine COVID-19 serious outcomesc19bromhexine.com 6/14/21Tau​2 = 0.00; I​2 = 0.0%; Z = 1.92 (p = 0.027)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ansarin (RCT)91%0.09 [0.01-1.59]death0/395/39Improvement, RR [CI]TreatmentControlAnsarin (RCT)89%0.11 [0.01-0.84]ventilation1/399/39Ansarin (RCT)82%0.18 [0.04-0.77]ICU2/3911/39Li (RCT)75%0.25 [0.06-1.00]no disch.2/124/6Li (RCT)50%0.50 [0.09-2.73]oxygen2/122/6Mareev (RCT)39%0.61 [0.14-0.97]no disch.14/2420/21Mareev (RCT)87%0.13 [0.01-2.25]viral+0/173/13Tolouian (RCT)76%0.24 [0.01-8.03]death4852Tolouian (RCT)76%0.24 [0.01-7.69]no improv.4852Tolouian (RCT)-75%1.75 [1.13-2.71]cases29/4818/52Mikhaylov (RCT)80%0.20 [0.01-3.97]hosp.0/252/25Mikhaylov (RCT)91%0.09 [0.01-1.56]symp. case0/255/25Mikhaylov (RCT)71%0.29 [0.07-1.24]viral+2/257/25bromhexine COVID-19 outcomesc19bromhexine.com 6/14/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit